Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Receivables - Other (2022 - 2025)

Historic Receivables - Other for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $2.6 million.

  • Taysha Gene Therapies' Receivables - Other changed 0.0% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $2.6 million for FY2024, which is 0.0% changed from last year.
  • Taysha Gene Therapies' Receivables - Other amounted to $2.6 million in Q3 2025, which was down 0.0% from $2.6 million recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Receivables - Other registered a high of $2.6 million during Q1 2022, and its lowest value of $2.6 million during Q1 2022.
  • In the last 4 years, Taysha Gene Therapies' Receivables - Other had a median value of $2.6 million in 2022 and averaged $2.6 million.
  • The largest annual percentage gain for Taysha Gene Therapies' Receivables - Other in the last 5 years was 0.0% (2023), contrasted with its biggest fall of 0.0% (2023).
  • Quarter analysis of 4 years shows Taysha Gene Therapies' Receivables - Other stood at $2.6 million in 2022, then changed by 0.0% to $2.6 million in 2023, then changed by 0.0% to $2.6 million in 2024, then changed by 0.0% to $2.6 million in 2025.
  • Its last three reported values are $2.6 million in Q3 2025, $2.6 million for Q2 2025, and $2.6 million during Q1 2025.